FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2050542368> ?p ?o ?g. }

• W2050542368 endingPage "355" @default.
• W2050542368 startingPage "355" @default.
• W2050542368 abstract "Bisphosphonate use and hip fracture epidemiology: ecologic proof from the contrary Alex Fisher1, Jodie Martin2, Wichat Srikusalanukul2, Michael Davis11Department of Geriatric Medicine, The Canberra Hospital, Canberra, ACT, Australia; 2Australian National University Medical School, Canberra, ACT, AustraliaAim: The objective of this article is to evaluate the relationship between the changes in prescriptions of antiosteoporotic drugs (mainly the rapid fall in the use of bisphosphonates [BPs]) and standardized hip fracture (HF) rates over the period 2005–2008 in the Australian Capital Territory (ACT).Methods: Annual sex- and age-specific HF rates (per 100,000 population) were determined and standardized using the Australian 2006 population census. Data on the annual prescriptions of BPs (mainly alendronate and risedronate), strontium ranelate, and hormone replacement therapy were obtained from the Australian Pharmaceutical Benefits Scheme (PBS) and Repatriation Australian Pharmaceutical Benefits Scheme (RPBS) databases.Results: In the ACT, the peak annual number of prescriptions for BPs was observed in 2006. Following reports linking osteonecrosis of the jaw with BP use, the number of BP prescriptions dropped by 14% in 2007–2008 compared with 2005, when the lowest HF rates were recorded. The reduction in BP prescriptions coincided with increased HF rates in females in 2007 (+22.6%) and in 2008 (+25.2%) compared with 2005; in males, HF incidence declined by 6.6% and 16.7%, respectively. The proportion of filled prescriptions for strontium ranelate, risedronate, and alendronate in 2007–2008 was 1:8.4:15.5, indicating that BPs were the dominant antiosteoporotic drugs. There was an inverse statistically significant relationship between the total annual number of BP prescriptions and standardized HF incidence rates for the 10-year period 1999–2008.Conclusion: Although currently there is no clear understanding of factors contributing to changing HF epidemiology, the available evidence suggests that much of the decline in HF rates is due to the use of BPs. The fall in the use of BPs is associated with an increase in HF rates in females, indicating that BPs should still be considered the first-line medications for the prevention and treatment of osteoporosis. Our results need to be confirmed in other populations and countries.Keywords: bisphosphonate use, hip fracture, epidemiology" @default.
• W2050542368 created "2016-06-24" @default.
• W2050542368 creator A5001250963 @default.
• W2050542368 creator A5037889491 @default.
• W2050542368 creator A5068197900 @default.
• W2050542368 creator A5082757316 @default.
• W2050542368 date "2010-11-01" @default.
• W2050542368 modified "2023-10-17" @default.
• W2050542368 title "Bisphosphonate use and hip fracture epidemiology: ecologic proof from the contrary" @default.
• W2050542368 cites W1850927048 @default.
• W2050542368 cites W1908985602 @default.
• W2050542368 cites W1963899208 @default.
• W2050542368 cites W1972948863 @default.
• W2050542368 cites W1975580061 @default.
• W2050542368 cites W1981220199 @default.
• W2050542368 cites W1982513519 @default.
• W2050542368 cites W1985133057 @default.
• W2050542368 cites W1990771263 @default.
• W2050542368 cites W1994799035 @default.
• W2050542368 cites W1996608840 @default.
• W2050542368 cites W1996654251 @default.
• W2050542368 cites W2000306595 @default.
• W2050542368 cites W2001013535 @default.
• W2050542368 cites W2001074839 @default.
• W2050542368 cites W2006558578 @default.
• W2050542368 cites W2016902222 @default.
• W2050542368 cites W2017581339 @default.
• W2050542368 cites W2021641144 @default.
• W2050542368 cites W2021829493 @default.
• W2050542368 cites W2022181568 @default.
• W2050542368 cites W2026344725 @default.
• W2050542368 cites W2031534650 @default.
• W2050542368 cites W2032829585 @default.
• W2050542368 cites W2033966101 @default.
• W2050542368 cites W2035445532 @default.
• W2050542368 cites W2036232268 @default.
• W2050542368 cites W2046617962 @default.
• W2050542368 cites W2048352241 @default.
• W2050542368 cites W2048353473 @default.
• W2050542368 cites W2048541373 @default.
• W2050542368 cites W2053375625 @default.
• W2050542368 cites W2056057966 @default.
• W2050542368 cites W2058476722 @default.
• W2050542368 cites W2061743346 @default.
• W2050542368 cites W2073511392 @default.
• W2050542368 cites W2078777841 @default.
• W2050542368 cites W2088866528 @default.
• W2050542368 cites W2090949699 @default.
• W2050542368 cites W2092619170 @default.
• W2050542368 cites W2097393515 @default.
• W2050542368 cites W2099336312 @default.
• W2050542368 cites W2101976393 @default.
• W2050542368 cites W2104518011 @default.
• W2050542368 cites W2106649747 @default.
• W2050542368 cites W2111025450 @default.
• W2050542368 cites W2117744034 @default.
• W2050542368 cites W2118377751 @default.
• W2050542368 cites W2119746366 @default.
• W2050542368 cites W2120080073 @default.
• W2050542368 cites W2124781717 @default.
• W2050542368 cites W2139507272 @default.
• W2050542368 cites W2144832496 @default.
• W2050542368 cites W2147725349 @default.
• W2050542368 cites W2150785441 @default.
• W2050542368 cites W2150904792 @default.
• W2050542368 cites W2151423418 @default.
• W2050542368 cites W2153538330 @default.
• W2050542368 cites W2155236480 @default.
• W2050542368 cites W2155984559 @default.
• W2050542368 cites W2160145148 @default.
• W2050542368 cites W2161546266 @default.
• W2050542368 cites W2163830908 @default.
• W2050542368 cites W2163852287 @default.
• W2050542368 cites W2167650352 @default.
• W2050542368 cites W2168484072 @default.
• W2050542368 cites W2172264400 @default.
• W2050542368 cites W2173649178 @default.
• W2050542368 cites W2132844569 @default.
• W2050542368 doi "https://doi.org/10.2147/cia.s13909" @default.
• W2050542368 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3010171" @default.
• W2050542368 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21228901" @default.
• W2050542368 hasPublicationYear "2010" @default.
• W2050542368 type Work @default.
• W2050542368 sameAs 2050542368 @default.
• W2050542368 citedByCount "34" @default.
• W2050542368 countsByYear W20505423682012 @default.
• W2050542368 countsByYear W20505423682013 @default.
• W2050542368 countsByYear W20505423682014 @default.
• W2050542368 countsByYear W20505423682015 @default.
• W2050542368 countsByYear W20505423682016 @default.
• W2050542368 countsByYear W20505423682017 @default.
• W2050542368 countsByYear W20505423682018 @default.
• W2050542368 countsByYear W20505423682019 @default.
• W2050542368 countsByYear W20505423682020 @default.
• W2050542368 countsByYear W20505423682021 @default.
• W2050542368 crossrefType "journal-article" @default.
• W2050542368 hasAuthorship W2050542368A5001250963 @default.
• W2050542368 hasAuthorship W2050542368A5037889491 @default.

• next